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Abstract
As of June 15, 2021, from 672,000 to 912,000 deaths have been averted through vaccination of 48% of the US population.
Because 52% remain unvaccinated, 728,000 to 988,000 lives remain at risk. These deaths can be spared, and the pandemic
stopped in its tracks provided a ﬁnal national vaccination rate of 84% is achieved. We aim to demonstrate in our analysis
the number of lives saved that can be attributed to CV-19 vaccination vs the mortality rate of natural infection seen in
unvaccinated individuals. However, time is short given the recent exponential rise of the highly contagious SARS-CoV-2
Delta variant. Delta infection results in a thousand-fold increase in viral load and a transmissibility 2.25x that of the
original SARS-CoV-2 strain. Predominance of the Delta variant has already resulted in Covid-19 surges in area with low
vaccination rates. An aggressive and timely vaccination campaign is being attempted. We hope our analysis helps
convince individuals ‘on the fence’ that vaccination is essential if the pandemic is to be ended in the United States.
Keywords: Covid-19 vaccination, Vaccination rates, 7-day Covid-19 positivity rates, Covid-19 variants of concern, Delta
variant

1. Introduction

F

rom the beginning of the Covid-19 (CV-19)
pandemic through 7/19/2021, 190 million cases
and 4.09 million deaths have been reported worldwide. Statistics for the United States are 34 million
cases and 608,000 deaths. Advances in treatment for
CV-19 may have ameliorated mortality by 25% but
deﬁnitive primary preventive treatment appears to
be CV-19 vaccination which results in a high percentage of protection. Here we aim to demonstrate
the magnitude of the effect of vaccination on CV-19
mortality, the threshold needed to stop the
pandemic and the reason we are witnessing a surge
in CV-19 cases and deaths. Data on the SARS-CoV-2
Delta variant, which as of this writing has

supplanted all remaining strains, are particularly
alarming and discussed below.

2. Methods
Seven-day average CV-19 positivity rates
were obtained from Johns Hopkins data as of 6/15/
21:
(https://www.coronavirus.jhu.edu>testing>
individual-states). Apparently, Florida was not
reporting that week (nor for several days after) as
their rate was quoted as “0%”da rate not obtained
by any other state and inconsistent with their previous 30-day running average. Thus only 49 states
were included in the analysis. State data on % of
the population fully vaccinated were obtained
from
Beckers
Hospital
Review:
(https://
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beckershospitalreview.com>public-health) as of the
same date. Data on the US population were obtained from Census Bureau records: (https://
www.census.gov>topics.population). Data on the
range of vaccination in New York State were obtained from the site https://www.covid19vaccine.
health.ny.gov/vaccination-rates-zip-code. Data on
prevalence of strains in Washington State were obtained from Washington State Department of
Health1

3. Results
3.1. Predictions of CV-19 mortality without
vaccination
As of 6/15/2021 there have been approximately
600,000 deaths in US owing to SARS-CoV-2 infection. During that time 33,060,171 individuals, clinically diagnosed, have survived infection. As the US
census is currently 331 million, the natural immunity for this group is 10%. There is also a group of
individuals who survived infection but were never
formally diagnosed, presumably owing to an
asymptomatic or minimally symptomatic infection.
They were not included in the “known” cases
because they never presented for formal diagnosis.
Their presence and quantiﬁcation have been provided by measuring the proportion of the US population that has antibodies to SARS-CoV-2. This
number stood at 22.1% as measured for the last two
weeks of May 2021.17
Most experts predict herd immunity and a stop to
the pandemic once an immunity rate of 70% is achieved. This translates into an additional 1.9 million
deaths to attain herd immunity (600,000  70%/
22.1%) or a ﬁnal toll of 2.5 million deaths had the
pandemic been allowed to take its natural course.
Might advances in CV-19 therapy with Remdesivir, dexamethasone and tocilizumab affect the above
estimate? Remdesivir has been shown to hasten
recovery in hospitalized patients but to date has not
demonstrated any statistically signiﬁcant effect on
CV-19 mortality.2 Dexamethasone, in one large
meta-analysis, was associated with a decrease in
CV-19 mortality of 28%3 although another large
meta-analysis failed to demonstrate any difference.4
Perhaps the most optimistic and authoritative
analysis is the RECOVERY Collaborative Group
study which randomized 2104 patients to dexamethasone and 4321 to usual care. For patients
requiring mechanical ventilatory support, mortality
was decreased 36%; for patients requiring oxygen

18%; for patients with no requirement for supplemental oxygen mortality was higher than without
this intervention.5
An early Italian observational study demonstrated
the beneﬁt of tocilizumab in CV-19 patients.6 Subsequently, two randomized trials found higher
mortality in the tocilizumab arm than in the placebo
arm.7,8 The RECOVERY Collaborative Group found
that tocilizumab effects a 15% reduction in Covid-19
mortality when coupled with dexamethasone
therapy.9
Although it is difﬁcult to translate these ﬁnding
into a ﬁrm estimate of the total net effect of therapy
on CV-19 mortality, a reasonable assumption may
be a 25% overall reduction in mortality. This modiﬁes the above estimate to an additional 1.4 million
(1.9 x 0.75) or 2.0 million total deaths.
3.2. Lives saved, lives still at peril
As of 6/15/21, 48% of the population had been fully
vaccinated preventing between 672,000e912,000
deaths: 0.48 x (1.4e1.9 million). 52% of lives are still in
jeopardy since they are not vaccinated. This works
out to 0.52 x (1.4e1.9 million) or an additional
728,000e988,000 deaths that might be spared through
Covid-19 vaccination.
3.3. Relationship between state CV 19 vaccination
rates and seven-day average positivity rates
An analysis of data for 41 inlier states reveals a
logarithmic relationship between vaccination rates
and average seven-day CV-19 positivity rates (see
Fig. 1). Eight states are high outliers-also conforming to a logarithmic relationship but with a higher
average weekly positivity level. High outliers will be
discussed in a separate section.
Once positivity becomes lower than 1%, personto-person CV-19 transmission rates are hampered
and by 0.5% should naturally extinguish. As per the
curve, a positivity rate of 0.42% is achieved at a
vaccination rate of 60%.
No state has yet to reach a 0% seven-day positivity
rate. This is explained by heterogeneity in vaccination rates. For example, for New York State, average
vaccination as of 6/15 was 50.3%. However, a Zip
code by Zip code analysis shows that regional
vaccination rates vary from 0 to 99þ%. Pockets of
low vaccination rates continue to serve as breeding
grounds and reservoirs for CV-19, thus preventing
total eradication.
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Fig. 1. Percent of total population fully vaccinated against COVID-19 versus seven-day average COVID-19 positivty rate.
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Table 1. Percent total population vaccinated against CV-19 versus
seven-day average CV-19 positivity rate (Data as of 6/15/21).
State

% Vaccinated

7d Positivity %

Mississippi
Alabama
Arkansas
Louisiana
Wyoming
Tennessee
Georgia
Idaho
Utah
Oklahoma
W. Virginia
S. Carolina
Missouri
N. Dakota
N. Carolina
Arizona
Indiana
Texas
Nevada
Kansas
Montana
Kentucky
Alaska
Ohio
Illinois
S Dakota
Nebraska
Michigan
Iowa
Delaware
California
Wisconsin
Pennsylvania
Colorado
Virginia
Minnesota
Hawaii
Oregon
New Mexico
New York
Washington
Maryland
New Jersey
New Hamp.
Rhode Island
Connecticut
Maine
Massachusetts
Vermont

28.1
30.6
32.6
33
33
33.6
33.9
34.5
34.7
35.2
35.7
36
36.5
37.7
37.8
38
38
38.1
39.1
40
40.6
40.8
41.1
42.3
42.9
43.9
44.2
44.7
45.9
46.3
46.6
46.8
47.0
48.3
48.4
48.9
49.5
49.5
50.2
50.3
50.7
52
52.5
53.2
55.4
57.2
58
58
61.9

8.33
9.41
8.84
3.15
5.6
2.72
2.72
11.77
6.01
7.86
2.04
1.88
7.57
3.98
2.81
2.59
2.50
5.19
4.58
11.59
2.91
4.20
0.83
1.94
0.83
1.82
1.19
1.54
7.35
1.15
0.63
1.17
1.96
3.74
1.47
1.31
1.09
3.27
1.53
0.41
3.80
0.62
5.75
1.29
0.51
0.57
1.88
0.36
0.61

For the 41 inlier states the logarithmic relationship predicts 5%
positivity at 34.1% vaccination rate; 4% at 36.5; 3% at 36.5; 2% at
43.7; 1% at 51.0; 0.5% at 58.2.
For the 8 high-outlier states (in bold) the logarithmic relationship
predicts 5% positivity at 48.6% vaccination rate; 4% at 51.7; 3% at
55.8; 2% at 61.7; 1% at 71.6; 0.5% at 81.6.

3.4. CV-19 variants of concern
Eight states, although they ﬁt a similar logarithmic
curve, have much higher CV-19 seven-day average
positivity rates for any given level of total vaccination

(Fig. 1 and Table 1). Although adherence to masking,
social distancing, hand hygiene and avoidance of
crowded gatherings may be in part responsible, there
is the possibility that these states were infected by
strains of CV-19 with higher person-to-person transmissibility. The best documentation of prevalence of
“variants of concern” comes from the Washington
State Department of Health.
As of the end of June, the B.1.1.7 alpha (UK) strain,
with 1.5 time the transmissibility of the wild-type
strain10 was responsible for 55% of CV-19 infections
in the state. Also on the rise, is the P.1 gamma
(Brazilian) strain with twice the transmissibility11 at
16.3% of all CV-19 infections.1
A comparison of the slopes of the inlier versus
outlier states suggest that, if the difference in the
two is owing to strains with higher transmissibility,
the CV-19 variants infecting these states were, on
average, 1.23-fold more transmissible.
3.5. The SARS-CoV-2 delta variant has supplanted
all other strains in the US
The Delta variant of CV-19 is 1.5-fold more
transmissible than the B.1.1.7 Alpha (UK) strain12.
The Alpha strain is already 1.5-fold more contagious
than the original wild type 19A/19B strain10. Thus,
Delta is 2.25 x more transmissible overall. A study of
167 Chinese individuals with the Delta strain
revealed viral loads approximately 1000 times those
seen for wild type 19A/19B.13
This enhanced transmissibility has allowed this
variant to eclipse all other SARS-CoV-2 strains in a
span of just six weeks. Two-week prevalence of the
Delta variant in new CV-19 cases increased eightfold in this short period of time: June 5e10.1%;
June 19e30.4%; July 3e51.7%; July 17e83%.14
Concomitant with the rise in prevalence of the
Delta variant, the national 7-day CV-19 average
positivity rate has doubled from 2 to 4% in just one
month (6/15-7/16).
An analysis from Scotland reveals that 70% of
those infected with the Delta variant have no relevant comorbidities. Infections were more severe in
that the hospitalization rate for Delta was approximately double that seen for those infected with the
Alpha variant. Lethality of this strain has yet to be
determined in that deaths lag signiﬁcantly behind
hospitalizations. CV-19 vaccination still provides
adequate levels of protection against the Delta
variant.15
Owing to its high level of transmissibility, the
Delta strain has caused a CV-19 surge in areas with
low vaccination rates. These surges, in turn, will
likely lead to poorer CV-19 survival rates. Data from

558 US hospitals reveal that during surge months
mortality rates can increase up to two-fold.16
The Delta variant threatens to compress the time
for vaccine intervention from years to just months.
This mandates post-haste persuasion of another 36%
of the population to accept vaccination (see below).
3.6. Vaccination levels required to defeat the
pandemic
Experts have predicted an end to the CV-19
pandemic once herd immunity of 70% is achieved.
The nation met this threshold on June 15 with 22%
natural and 48% vaccine immunity. Why, then, have
we since witnessed an increase in CV-19 cases,
hospitalizations and deaths rather than an end to
the pandemic? The answer is two-fold.
First, owing to the wide disparity in CV-19 vaccination rates, the populace has been divided into two
distinct silos. Half are protected through vaccination
while the other half remains vulnerable and provides fertile ground for the continued propagation
of SARS-CoV-2 virus.
Second, the Delta virus has eclipsed all other
strains in the United States. Its greatly enhanced
transmissibility has raised the entire nation (not just
eight states) from inlier to a status exceeding the
outlier curve. On June 15, the national vaccination
rate was 48% and the seven-day average CV-19
positivity rate stood at 2%. Correspondingly, the
logarithmic curves (see Fig. 1 and Table 1) predicted
a 1.98% positivity rate: (41 inlier states x predicted
1.324% plus 8 outlier states x predicted 5.309%-all
divided by 49).
Just one month later, the national positivity rate
had risen to 4% with a 49% vaccination rate. The
outlier curve at this point predicted a rate of 4.9%.
As of this writing (July 27, 2021), the seven-day
average is at 5.8% with a 49.7% vaccination rate-a
value exceeding that predicted from the outlier
curve by more than 1% (a 4.6% prediction).
Extrapolation of the outlier curve predicts a 1%
positivity at 72% total vaccination. It reaches 0.5% (a
rate at which the spread of Covid-19 should naturally extinguishdsee above) once 82% of the population has been vaccinated. Again, as of the end of
July the expectations of the outlier curve have been
exceeded.
A much simpler and straight forward analysis,
that yields a comparable answer, is to ﬁnd the level
of vaccination needed to bring the remaining 52% of
the unvaccinated population to 70% immunity. This
works out to be an additional 52% x 0.7 or 36% of the

5

total population. A ﬁnal ﬁgure to end the pandemic
is thus 48 þ 36 or an 84% total vaccination rate.

4. Discussion
Left to its natural course, the CV-19 pandemic
would, over a three to four-year span of time, have
resulted in a US death toll of 2.0e2.5 million lives.
Covid-19 vaccination has already prevented 672e912
thousand deaths. If an additional 728 to 988 thousand
deaths are to be averted, a vaccination rate of 84% of
the nation's population must be achieved (36% in
addition to the present 48%). Because the extremely
transmissible Delta variant has compressed the time
course of the pandemic from years-long to perhaps 6
months, time is of the essence in vaccinating the
remainder of the US population at risk.
Conﬂict of interest
The authors report no conﬂicts of interest.

Addendum
Subsequent to the Delta variant dominance (discussed in this article) the Omicron variant has
appeared and is quickly supplanting Delta as the
dominant SARS-CoV-2 strain in the United States
(1).
The 36 amino acid substitutions in the Omicron
Spike (S) protein have rendered it more resistant to
vaccine-induced immunity.
Analysis of the recent London accelerated
outbreak of SARS-CoV-2 infections, reported by the
Imperial College of London, suggests that “fully
vaccinated” (2-dose of Pﬁzer/Moderna) individuals
are protected from severe illness (hospitalization)
only in the range of 0e20% (2) while those who
received their third, booster dose are protected at
the 80% level (95% conﬁdence level 76.3e83.2%).
Though not as high as the booster effect on Delta
(96.5% protection with 95% CL 96.1e96.8%), vaccination remains the intervention most likely to end
the CV-19 pandemic (3).
William A Haseltine. Understanding Omicron:
Changes in The Spike Protein and Beyond And
What They Portend, Part 2. forbes.com/sites/
williamhaseltine/2021/12/10/omicron-the-sum-ofall-fears-part2/?sh¼d802fac2223a
Report 49: Vaccine Effectiveness against symptomatic
infection.
Imperial.ac.UK/mrc-global-infectiousdisease-analysis/covid-19/report-49-omicron
Report 48: The value of vaccine booster doses
to mitigate the global impact of the Omicron SARS-
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Variant.
Imperial.ac.UK/mrc-globalinfectious-disease-analysis/report-48-omicron
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